Look back at pharma news in the week to April 17, 2020
By Barbara Obstoj-Cardwell. Editor
Among last week’s news of note, Alnylam seems to have had a windfall in terms of a deal with Blackstone that, in exchange for royalty rights on inclisiran, a potential treatment for heterozygous familial hypercholesterolemia, it will get $2 billion funding. On the regulatory front, AstraZeneca gained US Food and Drug Administration approval for its rare disease drug Koselugo (selumetinib). Standing out among a significant amount of novel coronavirus news, was the planned collaboration of two ‘Big Pharmas’ – GlaxoSmithKline and Sanofi – to work on a potential COVID-19 vaccine. Also, although reports from Chinese trials on Gilead Sciences’ candidate remdesivir were disappointing, the company’s own studies, which have yet to report officially, anecdotally, show more promise.
Inclisiran keeps on giving
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze